SSC Phase 13 Answer Key 2025 : SSC Selection Post Answer Key 2025 is likely to be released soon by the Staff Selection Commission. The SSC Selection Post Phase 13 Answer Key 2025 which is generally ...
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary ...
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b ...
Hosted on MSN
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025
Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs. Key milestones included ...
Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion ...
GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...
PORTO, Portugal--(BUSINESS WIRE)--Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that 75% of patients currently enrolled in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results